Instrument NameMerus N.V. CSInstrument Symbol(MRUS-Q)

Instrument ExchangeNASDAQ

/CNW/ -- USA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to improve survival rates. Johns...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – Pancreatic cancer is among the deadliest cancers, prompting...

/CNW/ -- USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic...

USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic cancer patients through earlier detection, as according to Johns Hopkins Medicine up to 80% of...

USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage pancreatic cancer with 97% accuracy. This breakthrough is crucial, as Johns Hopkins Medicine...

/PRNewswire/ -- USA News Group - Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy...

USA News Group – Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the deadliest cancers on earth, analysis...

- Clinical update of zenocutuzumab (Zeno) presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Zeno represents a potential...

34% overall response rate in 79 evaluable patients with measurable disease9.1 months median duration of responseTumor reduction in 70% of patientsZeno...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing...

- Robust 34% overall response rate and 9.1 months median duration of response across multiple NRG1+ tumor types - Zenocutuzumab observed to be...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing...

- Zenocutuzumab clinical abstract selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting- Company to host...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a...

– MCLA-129 promotes Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cell-Mediated Phagocytosis (ADCP) of non-small cell lung...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that it has appointed...

- The poster details the mechanism of action of MCLA-129 in vitro and effectiveness in vivo in an EGFR exon20 insertion (ex20ins) non-small cell lung...

As of February 2022, more than 100 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a...

VANCOUVER – USA News Group – So far in 2022, there have already been some impressive developments in the battle against breast cancer, which over the last decade has been the leading killer of female cancer patients, according to a...

- The primary endpoint of Clinical Benefit Rate at 24 weeks with the triplet combination was met - The triplet combination showed clinically meaningful...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a...

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a...